Face2Gene Revenue and Competitors

Building AI-based Phenotyping Technologies Imagine a world where every person's genome serves as their medical record to guide health decisions. We're well on our way—genomic analysis is becoming the clinical standard in diagnostic evaluations, and artificial intelligence is the cornerstone of technologies that enable it. Used by 70% of the world's geneticists across 2,000 clinical sites in over 130 countries, FDNA's next-generation phenotyping (NGP) technologies capture, structure and analyze complex human physiological data to produce actionable genomic insights. FDNA's database includes an unprecedented depth of phenotypic and genotypic information associated with more than 10,000 diseases, crowdsourced from real-world patient cases through our broad network of users. This de-identified data is collected and stored in a private and secure cloud-based clinical warehouse, and integrated to LIMS, EMR and variant interpretation systems through a set of open APIs. While our roots stem from facial recognition, our future lies in the phenotype, and as a leader in AI we aim to always provide innovative, impactful solutions. Since its founding in 2011, FDNA continues to aid clinicians, researchers and genetic testing labs in finding answers and treatments for hundreds-of-millions of patients globally living with a genetic disease.